Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects (good and bad) a combination of
cytoxan, epirubicin, and capecitabine have on women with Stage II/II/IIIA breast cancer.
Phase:
N/A
Details
Lead Sponsor:
Craig A. Bunnell, MD, MPH
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Massachusetts General Hospital Pharmacia